Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

This study has been completed.
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC Identifier:
First received: December 3, 2010
Last updated: April 21, 2014
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 26, 2014